echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > BeiGene anti-PD-1 antibody approved for two new indications

    BeiGene anti-PD-1 antibody approved for two new indications

    • Last Update: 2021-08-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On the evening of June 22, the official website of the National Medical Products Administration (NMPA) of China announced that BeiGene's new anti-PD-1 antibody drug tislelizumab has launched two new indications (sDNA) for lung cancer and liver cancer.


    According to a press release issued by BeiGene, the indications for these two sDNAs are: combined chemotherapy for the treatment of patients with first-line advanced non-squamous non-small cell lung cancer (NSCLC), and treatment of unresectable livers that have received previous treatment.


    Screenshot source: NMPA official website

    The approval of the NMPA makes tislelizumab a first-line immunotherapy for patients with advanced squamous and non-squamous non-small cell lung cancer


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.